Renal Cell Carcinoma - KOL Insight

Gain insights from leading KOLs on the latest trends in RCC treatment, including the steady use of Opdivo/Yervoy, the rising role of Keytruda, and the broad efficacy of Cabometyx. Discover how clinical trials and patient characteristics are shaping the future of RCC therapy.

Key brands covered in this report:

• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Cabometyx (cabozantinib)
• Imfinzi (durvalumab)
• Tecentriq (atezolizumab)
• Welireg (belzutifan)

Key questions answered:

• What are the preferred therapies for RCC, and what factors influence these choices?
• What is the expert consensus on approved RCC treatments like Opdivo, Keytruda, Cabometyx and Lenvima/Kisplyx?
• What are the most promising late-stage pipeline drugs or classes and other novel approaches for RCC?
• What must new pipeline products show in terms of safety and efficacy to gain regulatory approval and compete with current leaders, and what are their chances?
• How do patient characteristics (risk group, performance status, co-morbidities) influence RCC treatment decisions, and how will emerging treatments fit into these specific populations?
• Which advanced clinical trials have the greatest potential to change prescribing habits, and how could their outcomes impact future practice?
• How is the RCC treatment landscape expected to evolve for each patient category and treatment line in the coming years?

Companies:

Novartis, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Incyte, Exelixis, Ipsen, AVEO Oncology, Xynomic Pharma, Hutchmed.